Sterile Water

Water


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-7385
Sterile Water also known as Water is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Sterile Water is 0264-7385. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Sterile Water drug includes Water - 1 mL/mL . The currest status of Sterile Water drug is Active.

Drug Information:

Drug NDC: 0264-7385
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sterile Water
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Water
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:WATER - 1 mL/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 04 Sep, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 17 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019633
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:059QF0KO0R
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-7385-504 CONTAINER in 1 CASE (0264-7385-50) / 2000 mL in 1 CONTAINER04 Sep, 2014N/ANo
0264-7385-604 CONTAINER in 1 CASE (0264-7385-60) / 3000 mL in 1 CONTAINER04 Sep, 2014N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sterile water water water water

Indications and Usage:

Indications and usage sterile water for injection usp is indicated for use in adults and pediatric patients as a diluent in the aseptic preparation of parenteral solutions or as a vehicle for drug administration after admixture or dilution.

Warnings:

Warnings this solution is for compounding only, not for direct infusion. hypotonic and hemolytic. do not inject until made approximately isotonic by addition of an appropriate solute, due to the possibility of hemolysis. the administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk of dilutional states is inversely proportional to the electrolyte concentration. warning: this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 m
cg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. tissue loading may occur at even lower rates of administration.

General Precautions:

General to minimize the risk of possible incompatibilities arising from the mixing of additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration. do not use plastic container in series connection. if administration of sterile water for injection usp after admixture or dilution is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. if administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmhg) causing distortion to the container such as wringing or twisting. such handling could result in breakage of the container. this solution is intended for intravenous administration after admixture or dilution using sterile equipment. it is recommended that intravenous administration apparatus be replaced at least once every 24 hours. u
se only if solution is clear and container and seals are intact. the drug product contains no more than 25 mcg/l of aluminum.

Dosage and Administration:

Dosage and administration this solution is for intravenous use only after admixture or dilution. do not inject until made approximately isotonic by addition of appropriate solute. following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. see directions accompanying drugs. the dosage and administration of sterile water for injection usp is dependent upon the recommended dosage and administration of the solute used. fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. some additives may be incompatible. consult with pharmacist. when performing admixture or dilution, use aseptic techniques. mix thoroughly. do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications:

Contraindications none known.

Adverse Reactions:

Adverse reactions refer to the package insert of the solute used. reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. the physician should also be alert to the possibility of adverse reactions to drug additives. prescribing information for drug additives to be administered in this manner should be consulted. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Use in Pregnancy:

Usage in pregnancy refer to the package insert of the solute used.

Pediatric Use:

Pediatric use refer to the package insert of the solute used. see warnings section regarding aluminum.

Geriatric Use:

Geriatric use refer to the package insert of the solute used. see warnings section regarding aluminum.

Overdosage:

Overdosage overdosage (hypotonic expansion) is a function of an increase in fluid intake over fluid output, and occurs when the increase in the volume of body fluids is due to water alone. overdosage may occur in patients who receive large quantities of electrolyte-free water to replace abnormal excessive fluid losses, in patients whose renal tolerance to water loads is exceeded, or in patients who retain water postoperatively in response to stress. manifestations of water intoxication are behavioral changes (confusion, apathy, disorientation and attendant hyponatremia), central nervous system disturbances (weakness, muscle twitching, headaches, nausea, vomiting, convulsions) and weight gain. treatment consists of withholding fluids until excessive water is excreted. in severe hyponatremia it may be necessary to cautiously administer hypertonic saline to increase extracellular osmotic pressure and excretion of excess water by the kidneys.

Description:

Description sterile water for injection usp is a clear, colorless, odorless liquid. it is sterile, hypotonic, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. sterile water for injection usp is a diluent suitable for intravascular injection after first having been made approximately isotonic by the addition of suitable solute. ph: 5.5 (5.0-7.0) not made with natural rubber latex, pvc or dehp. the plastic container is made from a multilayered film specifically developed for parenteral drugs. it contains no plasticizers and exhibits virtually no leachables. the solution contact layer is a rubberized copolymer of ethylene and propylene. the container is nontoxic and biologically inert. the container-solution unit is a closed system and is not dependent upon entry of external air during use. the container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

Clinical Pharmacology:

Clinical pharmacology sterile water for injection usp is used as a diluent for other parenteral drugs. as such, sterile water for injection usp contributes to the water for hydration when provided in parenteral drug and fluid therapy, after the introduction of suitable additives and/or mixture with suitable solutes to approximate isotonicity.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility refer to the package insert of the solute used.

How Supplied:

How supplied sterile water for injection usp is supplied in 2000 and 3000 ml pharmacy bulk package containers packaged 4 per case. ndc ref size 0264-7385-50 s8505 2000 ml 0264-7385-60 s8506 3000 ml exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. protect from freezing. it is recommended that the product be stored at room temperature (25°c); however, brief exposure up to 40°c does not adversely affect the product.

Spl Patient Package Insert:

Directions for use of plastic container warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration and final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration, whenever solution and container permit. use of a final filter is recommended during administration of all parenteral solutions where possible. sterile water for injection usp in the pharmacy bulk package is intended for use in the preparation of sterile, intravenous admixtures. additives may be incompatible with the fluid withdrawn from this container. complete information is not available. those additives known to be incompatible should not be used. consult with pharmacist, if available. when compounding admixtures, use aseptic technique. mix thoroughly.
do not store any unused portion of sterile water for injection usp. preparation inspect overwrap and primary bag. do not use if overwrap has been damaged. do not use unless solution is clear and closure is intact. 1. to open: tear overwrap starting from the tear notches. (figure 1) for pharmacy bulk packages the pharmacy bulk package is to be used only in a suitable work area such as a laminar air flow hood (or an equivalent clean air compounding area). for compounding only. do not use for direct infusion. do not use/penetrate blocked port (see figure 2, left upper corner). suspend container. remove aluminum foil of set port at the bottom of container (see figure 3). attach suitable transfer device or compounding set (figure 2). refer to complete directions accompanying device. hang bag on suitable fixture (figure 4). once container closure has been penetrated, withdrawal of content should be completed within 4 hours. important admixing instructions the contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for infusion or, through a sterile transfer device, for the filling of empty sterile syringes. additives may be incompatible with the fluid withdrawn from this container. consult with pharmacist, if available. when compounding admixtures, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution container permits. (see precautions, general ) . tear notches, overwrap illustration figure 1 bag hanger, set port (green ring), blocked port (red ring) illustration figure 2 figure 3 figure 4

Package Label Principal Display Panel:

Principal display panel - 2000 ml sterile water for injection usp warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. ref s8505 ndc 0264-7385-50 lot exp. 2000 ml pharmacy bulk package not for direct infusion no antimicrobial agent or other substance has been added. sterile. pharmacy bulk package container. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. contains no more than 25 mcg/l of aluminum recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. do not remove overwrap until ready for use. once container closure has been penetrated, withdrawal of content should be completed within 4 hours. see package insert. not made with natural rubber latex, pvc or dehp. rx only y38-000-065 ld-455-3 b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 set sterile water injection 2l container label recycle symbol sterile water injection 2l container label

Principal display panel - 3000 ml sterile water for injection usp warning: hypotonic and hemolytic. do not inject until made approximately isotonic by addition of appropriate solute. ref s8506 ndc 0264-7385-60 lot exp. 3000 ml pharmacy bulk package not for direct infusion no antimicrobial agent or other substance has been added. sterile. pharmacy bulk package container. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. contains no more than 25 mcg/l of aluminum recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. do not remove overwrap until ready for use. once container closure has been penetrated, withdrawal of content should be completed within 4 hours. see package insert. not made with natural rubber latex, pvc or dehp. rx only y38-000-066 ld-456-3 b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 set recycle symbol 3000 ml container label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.